News of Note—NIH Zika vaccine, Emergent BioSciences and more

In this week's vaccine News of Note, Emergent BioSciences completed an acquisition of Sanofi's smallpox vaccine business.

Here is some other vaccine news of note for this week.

> A team from George Washington University is testing an NIH-developed Zika vaccine in Brazil. Release

> NIAID Director Anthony Fauci, M.D., believes a "durable" end to the HIV and AIDS epidemic will require an effective vaccine. Release

> Ex-GSK vaccine and pharma exec Abbas Hussain joined C-Bridge Capital as a senior partner. FierceBiotech story

Emergent BioSciences finished its purchase of Sanofi's smallpox vaccine unit. Release

> A study found that AstraZeneca's FluMist was 46% effective, but a flu expert cited concerns. CIDRAP story

> Enesi Pharma launched with the goal to develop novel solid-dose vaccines against various diseases. Release

> In a recent survey, 87% of physicians said they believe GlaxoSmithKline's Shingrix is an important vaccine development. Medscape story